Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)

Overview and Investment Opinion

In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and…
Read more…

Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)

Investment Thesis

This has been a very disappointing year for Antares investors; the stock closed at $2.57 on December 31, 2014…
Read more…

Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)

Introduction to Report

One of my assets is also one of my biggest drawbacks. When I am writing on a Company…
Read more…

Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)

Investment Overview

Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional…
Read more…

Antares: Highlights of CEOs Presentation at Piper Jaffray Conference (ATRS, Buy, $2.46)

Overview

I tuned in to the Antares presentation at the Piper Jaffrey conference on December 2, 2014 to listen to what…
Read more…

Antares Pharmaceuticals: An Update on Key Issues (ATRS, Buy, $2.14)

Investment Thesis

Antares (ATRS) common has been hit with a storm of concerns that has caused the stock to decline from…
Read more…